Continue Reading Below
What: According to data provided by S&P Capital IQ, the anti-obesity drugmaker Arena Pharmaceuticals lost nearly 16% of its value in December. Given the lack of any obvious negative catalysts during the month, this downward move was probably the result of investors shedding the laggards in their portfolios at the end of the year for tax purposes.
So what: Arena's shares dropped by 47% last year because of the sluggish sales for its fat-fighting pill Belviq that's marketed by the Japanese drugmaker Eisai. For the entirety of 2015, for instance, Arena is only expected to book around $38 million in total revenue. While the Street does expect Arena's revenue to jump to $47.8 million in 2016, the company will likely still be cash flow negative this year, and probably for several years to come.
Now what: Arena and its competitor Orexigen Therapeutics have found out first hand just how tough it is to successfully market an FDA-approved weight loss medicine. Because of the lack of long-term safety on these drugs, private and public payers have been slow to offer coverage, meaning that the only option many potential patients have to try these new drugs is to pay out-of-pocket. That's rarely turned out to be a winning strategy for a prescription medicine.
So, despite Arena and Eisai submitting a New Drug Application to the FDA for anextended-release formulation of Belviq last November, it's hard to imagine the drug's sales picking up in a meaningful way until more payers are on board. And that event doesn't appear likely until either Arena or Orexigen complete their ongoing cardiovascular outcomes trials. As such, investors will probably want to play it safe by remaining on the sidelines with these weight-loss drugmakers this year.
The article Arena Pharmaceuticals Ends 2015 On a Sour Note: Can It Recover in 2016? originally appeared on Fool.com.
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
Continue Reading Below